Xilio Therapeutics, Inc. (XLO) — Institutional Holders, Q2 2026
27 institutional investment managers reported a XLO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $32.6M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
XLO in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- ORBIMED ADVISORSNew · +592,300 sh+$5.7M
- Stonepine Capital ManagementAdded · +161,832 sh+$1.6M
- ADAGE CAPITAL PARTNERS GP, L.L.C.New · +111,541 sh+$1.1M
- VANGUARD CAPITAL MANAGEMENTAdded · +54,857 sh+$525.5K
- CITADEL ADVISORSNew · +25,950 sh+$248.6K
Biggest sellers
- Caligan PartnersSold out · -112,128 sh-$1.1M
- FMRSold out · -36,558 sh-$350.2K
- Ghisallo Capital ManagementSold out · -13,800 sh-$132.2K
- VANGUARD FIDUCIARYTrimmed · -5,881 sh-$56.3K
- UBS Group AGTrimmed · -4,024 sh-$38.5K
XLO 13F holders ranked 1–27 of 27
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors#1 · 664,021 sh | 664,021 | $6.4M | 0.38% | 0.0% |
| 2 | GILEAD SCIENCES#2 · 650,389 sh | 650,389 | $6.2M | 0.38% | 0.0% |
| 3 | ORBIMED ADVISORS#3 · 592,300 sh | 592,300 | $5.7M | 0.11% | New |
| 4 | Frazier Life Sciences Management, L.P.#4 · 422,505 sh | 422,505 | $4.0M | 0.09% | 0.0% |
| 5 | Stonepine Capital Management#5 · 225,994 sh | 225,994 | $2.2M | 1.01% | +252.2% |
| 6 | VANGUARD CAPITAL MANAGEMENT#6 · 178,517 sh | 178,517 | $1.7M | 0.00% | +44.4% |
| 7 | Sio Capital Management#7 · 152,464 sh | 152,464 | $1.5M | 0.24% | 0.0% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C.#8 · 111,541 sh | 111,541 | $1.1M | <0.01% | New |
| 9 | Merck#9 · 105,982 sh | 105,982 | $1.0M | 0.19% | 0.0% |
| 10 | RENAISSANCE TECHNOLOGIES#10 · 64,153 sh | 64,153 | $614.6K | <0.01% | +29.4% |
| 11 | MORGAN STANLEY#11 · 56,954 sh | 56,954 | $545.6K | 0.00% | -0.9% |
| 12 | GEODE CAPITAL MANAGEMENT#12 · 39,055 sh | 39,055 | $374.2K | 0.00% | +5.0% |
| 13 | CITADEL ADVISORS#13 · 25,950 sh | 25,950 | $248.6K | 0.00% | New |
| 14 | VANGUARD FIDUCIARY#14 · 22,594 sh | 22,594 | $216.5K | 0.00% | -20.7% |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT#15 · 17,544 sh | 17,544 | $168.1K | <0.01% | New |
| 16 | TWO SIGMA INVESTMENTS#16 · 14,544 sh | 14,544 | $139.3K | <0.01% | New |
| 17 | Velan Capital Investment Management#17 · 14,285 sh | 14,285 | $136.8K | 0.08% | 0.0% |
| 18 | GSA CAPITAL PARTNERS LLP#18 · 13,590 sh | 13,590 | $130.0K | <0.01% | -19.8% |
| 19 | STATE STREET#19 · 13,311 sh | 13,311 | $127.5K | 0.00% | 0.0% |
| 20 | PRELUDE CAPITAL MANAGEMENT#20 · 11,600 sh | 11,600 | $111.1K | <0.01% | New |
| 21 | BlackRock#21 · 8,757 sh | 8,757 | $83.9K | 0.00% | New |
| 22 | Steward Partners Investment Advisory#22 · 714 sh | 714 | $6.8K | 0.00% | New |
| 23 | SECURITY NATIONAL BANK OF SIOUX CITY IOWA#23 · 321 sh | 321 | $3.1K | <0.01% | New |
| 24 | BARCLAYS PLC#24 · 115 sh | 115 | $1.1K | 0.00% | New |
| 25 | Key FInancial#25 · 59 sh | 59 | $565.00 | <0.01% | 0.0% |
| 26 | JONES FINANCIAL COMPANIES LLLP#26 · 29 sh | 29 | $262.00 | 0.00% | New |
| 27 | UBS Group AG#27 · 14 sh | 14 | $134.00 | 0.00% | -99.7% |
Funds that sold out of XLO in Q2 2026 (6)
Held XLO at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Caligan Partners112,128 sh | 112,128 | $943.0K |
| FMR36,558 sh | 36,558 | $307.5K |
| Ghisallo Capital Management13,800 sh | 13,800 | $116.1K |
| JPMORGAN CHASE240 sh | 240 | $2.0K |
| Vanguard Global Advisers210 sh | 210 | $1.8K |
| ROYAL BANK OF CANADA91 sh | 91 | $1.0K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.